Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection
Status:
Terminated
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
The symptoms of respiratory distress caused by COVID-19 may be reduced by drugs combining
anti-inflammatory and antiviral effects. This dual effect may simultaneously protect
severely-ill patients and reduce the viral load, therefore limiting virus dissemination We
want to demonstrate the superiority of naproxen (anti-inflamatory drug) treatment addition to
standard of care compared to standard of care in term of 30-day mortality.